Experience

Argo Biopharma Announces Multi-Asset License and Option Agreements With Novartis

September 3, 2025

Cooley advised Argo Biopharma, a clinical-stage biotechnology company focused on developing next-generation small interfering RNA (siRNA) therapeutics, on its additional strategic collaboration with Novartis for multiple cardiovascular assets in Argo’s pipeline.

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Jennifer Raab
Partner, Palo Alto
Freddy Yip
Associate, Hong Kong
Yuhan Wu
Associate, Palo Alto
Aaron Pomeroy
Partner, Colorado
Amanda Pacheco
Associate, Palo Alto
Julia R. Brinton
Special Counsel, Washington, DC
David Burns
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Mari Dugas
Associate, Washington, DC
Yiming Liu
Partner in Charge – Shanghai, Shanghai
Patrick Loofbourrow
Partner, Singapore
Phil Mitchell
Partner, New York
Bin Wang
Special Counsel, Palo Alto

Related Practices & Industries

Otsuka Pharmaceutical Announces Global Strategic Collaboration With Harbour BioMed

June 23, 2025

Cooley advised Otsuka Pharmaceutical, a total healthcare company focused on each individual’s potential to enhance their well-being, on its global strategic collaboration with Harbour BioMed to advance BCMAxCD3 bispecific T-cell engagers for treating autoimmune diseases.

Read more

Related contacts

Jennifer Raab
Partner, Palo Alto
Alison Freeman-Gleason
Of Counsel, Seattle
Rachel Thorn
Of counsel, New York
Zack Gong
Associate, Shanghai
Freddy Yip
Associate, Hong Kong
Jonathan Kaufman
Associate, Palo Alto
Natasha Leskovsek
Of Counsel, Washington, DC
Robert Eisenbach
Of Counsel, San Francisco
Amanda Pacheco
Associate, Palo Alto

Related Practices & Industries

Alumis Announces Merger With ACELYRIN

February 6, 2025

Cooley advised Alumis (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, on its definitive agreement with ACELYRIN to merge in an all-stock transaction.

Read more

Related contacts

Jamie Leigh
Partner, San Francisco
David Peinsipp
Partner, San Francisco
Ben Beerle
Partner, San Francisco
Kristin VanderPas
Partner, San Francisco
Polina A. Demina
Special Counsel, New York
Sangitha Palaniappa
Associate, Palo Alto
Christine Turner
Associate, Colorado
Shaun (Tianjie) Wang
Associate, New York
Megan Browdie
Partner, Washington, DC
Lauren Creel
Partner, Palo Alto
Ross Eberly
Partner, Santa Monica
Stephanie Gentile
Partner, New York
Sarah Lightdale
Partner, New York
Phil Mitchell
Partner, New York
Jeremy Morrison
Partner, Washington, DC
Alessandra Murata
Partner, Palo Alto
Jennifer Raab
Partner, Palo Alto
Patrick Van Eecke
Partner, Brussels
Natasha Leskovsek
Of Counsel, Washington, DC
Julia R. Brinton
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Caroline Vu
Special Counsel, Palo Alto
Christopher Andrews
Associate, New York
Dannielle Antone
Associate, San Francisco
Tamara Chin Loy
Associate, Washington, DC
Navya Dasari
Associate, New York
Joshua Elefant
Associate, Palo Alto
Winda Fung
Associate, Santa Monica
Wyatt Kernell
Associate, Colorado
Kristina Krasnikova
Associate, Palo Alto
Sunny J. Levine
Associate, Colorado
Amanda Lindner
Associate, New York
Jayne M. Munger
Associate, New York
Julianne Orr
Associate, San Francisco
Michael Pelle
Associate, New York
Breanna Qin
Associate, Palo Alto
Bartholomäus Regenhardt
Associate, Brussels
Jesse Schulman
Associate, Colorado
Freddy Yip
Associate, Hong Kong
Isabella Ysebrands
Associate, San Francisco

Related Practices & Industries

Geron Corporation Announces up to $375 Million in Funding With Royalty Pharma and Pharmakon Advisors

November 7, 2024

Cooley advised Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, on its up to $375 million in synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors.

Read more

Related contacts

Mischi a Marca
Partner, San Francisco
Shimeng Cheng
Special Counsel, San Francisco
Addison Pierce
Partner, Chicago
Chadwick Mills
Partner, San Francisco
Dr. Jon Cousin
Partner, Washington, DC
Xander Lee
Partner, Santa Monica
Jennifer Raab
Partner, Palo Alto
Ryan Blair
Partner, San Diego
Phil Mitchell
Partner, New York
Francis Wheeler
Senior Counsel, Colorado
Andrew Epstein
Special Counsel, Seattle
Marina Remennik
Special Counsel, Palo Alto
Karen Tsai
Special Counsel, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
John Forrest
Associate, Boston
Xueqing Li
Associate, San Francisco
Leo Spicer-Phelps
Partner, London
Dr. Jason Valentine
Associate, Washington, DC
Charles A. Watkins II
Associate, Santa Monica
Jennifer Fitzpatrick
Paralegal Specialist, Washington, DC
Chris Rhem
Paralegal Specialist, San Francisco

Related Practices & Industries

Foreseen Biotechnology Announces Exclusive Global Licensing Agreement With Ipsen

July 11, 2024

Cooley advised Foreseen Biotechnology – an emerging biotech company that pioneered a high-throughput integrated translational proteomics platform powered by an artificial intelligence-based data analytical system to accelerate the discovery of novel targets for therapeutics and diagnostics that are clinically relevant – on its exclusive global licensing agreement with Ipsen for FS001, an antibody-drug conjugate with first-in-class potential.

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Jennifer Raab
Partner, Palo Alto
Jiqiang Lin
Associate, New York
Robert Eisenbach
Of Counsel, San Francisco
Amanda Pacheco
Associate, Palo Alto
Xander Lee
Partner, Santa Monica
David Burns
Special Counsel, Washington, DC

Related Practices & Industries

View more

Memberships and affiliations

California Bar Association

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.